파인메딕스
Financials
Valuation Metrics
파인메딕스's Market Cap is ₩304B. At end of 2025 it was ₩422B. Ranked #2026 of 2,405 in KR market (top 84%), #1284 of 1,627 on KOSDAQ (top 79%), #84 of 94 in Health Care Equipment & Services (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 30.44B KRW | KR#2,026/2,405 Sec#84/94 |
| Revenue | 11.43B KRW | KR#2,261/2,405 Sec#80/94 |
| Net Income | -599.4M KRW | KR—/2,405 Sec—/94 |
| Total Assets | 24.15B KRW | KR#2,352/2,405 Sec#91/94 |
| Net Assets | 19.13B KRW | KR#2,290/2,405 Sec#89/94 |
| Employees | 74 | KR#1,844/2,405 Sec#73/94 |
| Value | ||
| P/B | 1.59x | KR#1,846/2,405 Sec#62/94 |
| P/S | 2.66x | KR#1,965/2,405 Sec#64/94 |
| FCF Yield | -11.45% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | -3.13% | KR#1,720/2,405 Sec#59/94 |
| ROA | -2.48% | KR#1,788/2,405 Sec#61/94 |
| Op. Margin | -10.21% | KR#1,979/2,405 Sec#63/94 |
| Revenue Growth | -4.39% | KR#1,736/2,405 Sec#76/94 |
| Financial Health | ||
| Debt Ratio | 26.24% | KR#500/2,405 Sec#27/94 |
| Total Debt | 1.93B KRW | KR#1,906/2,405 Sec#71/94 |
| FCF | -3.49B KRW | KR#1,414/2,405 Sec#49/94 |
| Cash | 4.07B KRW | KR#2,074/2,405 Sec#80/94 |
| Current Ratio | 10.83x | KR#86/2,405 Sec#11/94 |
| Performance | ||
| 1Y Return | -30.73% | KR#1,475/2,405 Sec#45/94 |
| 1M Return | -13.44% | KR#1,446/2,405 Sec#56/94 |
| From 52W High | -41.39% | KR#800/2,405 Sec#30/94 |
| 1Y MDD | -54.65% | KR#1,162/2,405 Sec#45/94 |
| Trading | ||
| Volume | 3,731 shares | KR#2,172/2,405 Sec#89/94 |
| Trading Value | 20.3M KRW | KR#2,087/2,405 Sec#83/94 |
| Foreign Own. | 1.17% | KR#1,947/2,405 Sec#70/94 |
| Per Share | ||
| EPS | -107 KRW | KR—/2,405 Sec—/94 |
| BPS | 3,400 KRW | KR#1,781/2,405 Sec#50/94 |
Company Info
Fine Medic, established in 2009, is a specialized manufacturer of advanced digestive endoscopic procedure instruments, listed on KOSDAQ in 2024. The company has localized endoscopic incision knives, snares, and injectors, securing over 20% domestic market share and expanding sales in Japan, Europe, and the U.S. based on CE and FDA certifications. Leveraging the CEO's more than 20 years of clinical experience, Fine Medic has established a unified development system to promptly productize the needs of the medical field. It is headquartered in Dong-gu, Daegu Metropolitan City.